| Shannon Rhea Hall, DNP, CRNP | |
|
74 Plaza Dr Bldg Iii, Pell City, AL 35125-9370 | |
| (205) 814-7221 | |
| (205) 812-8018 |
| Full Name | Shannon Rhea Hall |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 74 Plaza Dr Bldg Iii, Pell City, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417310921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | AG1015136 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Birmingham Internal Medicine Associates, Llc | 1658341193 | 121 |
News Archive
Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
In the largest study ever conducted with patients experiencing chronic and severe depression, researchers led by Dr. Scott Aaronson, Director of Clinical Research at Sheppard Pratt Health System have found that an implantable vagus nerve stimulation device paired with antidepressant treatment (which could include medications, psychotherapy, or electroconvulsive therapy proves effective in reducing symptoms among patients with treatment-resistant depression.
A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.
The world's leading mass spectrometer manufacturers have agreed to license technology that enabled University of Southern California (USC) researchers to develop software that, for the first time, allows scientists to easily use and share research data collected across proprietary platforms.
› Verified 4 days ago
| Entity Name | University Of Alabama Health Services Foundation, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093768723 PECOS PAC ID: 1951213107 Enrollment ID: O20031105000261 |
News Archive
Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
In the largest study ever conducted with patients experiencing chronic and severe depression, researchers led by Dr. Scott Aaronson, Director of Clinical Research at Sheppard Pratt Health System have found that an implantable vagus nerve stimulation device paired with antidepressant treatment (which could include medications, psychotherapy, or electroconvulsive therapy proves effective in reducing symptoms among patients with treatment-resistant depression.
A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.
The world's leading mass spectrometer manufacturers have agreed to license technology that enabled University of Southern California (USC) researchers to develop software that, for the first time, allows scientists to easily use and share research data collected across proprietary platforms.
› Verified 4 days ago
| Entity Name | Birmingham Internal Medicine Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598796542 PECOS PAC ID: 1658341193 Enrollment ID: O20040730000432 |
News Archive
Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
In the largest study ever conducted with patients experiencing chronic and severe depression, researchers led by Dr. Scott Aaronson, Director of Clinical Research at Sheppard Pratt Health System have found that an implantable vagus nerve stimulation device paired with antidepressant treatment (which could include medications, psychotherapy, or electroconvulsive therapy proves effective in reducing symptoms among patients with treatment-resistant depression.
A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.
The world's leading mass spectrometer manufacturers have agreed to license technology that enabled University of Southern California (USC) researchers to develop software that, for the first time, allows scientists to easily use and share research data collected across proprietary platforms.
› Verified 4 days ago
| Entity Name | Southern Pain Specialists, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174697106 PECOS PAC ID: 9032136429 Enrollment ID: O20051025000711 |
News Archive
Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
In the largest study ever conducted with patients experiencing chronic and severe depression, researchers led by Dr. Scott Aaronson, Director of Clinical Research at Sheppard Pratt Health System have found that an implantable vagus nerve stimulation device paired with antidepressant treatment (which could include medications, psychotherapy, or electroconvulsive therapy proves effective in reducing symptoms among patients with treatment-resistant depression.
A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.
The world's leading mass spectrometer manufacturers have agreed to license technology that enabled University of Southern California (USC) researchers to develop software that, for the first time, allows scientists to easily use and share research data collected across proprietary platforms.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shannon Rhea Hall, DNP, CRNP 74 Plaza Dr Bldg Iii, Pell City, AL 35125-9370 Ph: (205) 814-7221 | Shannon Rhea Hall, DNP, CRNP 74 Plaza Dr Bldg Iii, Pell City, AL 35125-9370 Ph: (205) 814-7221 |
News Archive
Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
In the largest study ever conducted with patients experiencing chronic and severe depression, researchers led by Dr. Scott Aaronson, Director of Clinical Research at Sheppard Pratt Health System have found that an implantable vagus nerve stimulation device paired with antidepressant treatment (which could include medications, psychotherapy, or electroconvulsive therapy proves effective in reducing symptoms among patients with treatment-resistant depression.
A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.
The world's leading mass spectrometer manufacturers have agreed to license technology that enabled University of Southern California (USC) researchers to develop software that, for the first time, allows scientists to easily use and share research data collected across proprietary platforms.
› Verified 4 days ago
Ms. Laura Paige Farris, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1508 Cogswell Ave, Pell City, AL 35125 Phone: 205-814-1526 | |
Justin Fuller, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 70 Plaza Dr, Pell City, AL 35125 Phone: 205-814-9284 Fax: 205-814-9626 | |
Wendy O'neal, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 41 Eminence Way Ste A, Pell City, AL 35128 Phone: 205-884-9000 | |
Erin Chrisla Martin, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 70 Plaza Dr, Pell City, AL 35125 Phone: 205-814-9284 Fax: 205-814-9626 | |
Angela K Belyeu, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 7067 Veterans Pkwy, Suite 130, Pell City, AL 35125 Phone: 205-884-9000 Fax: 205-884-8111 | |
Kelsie W Roulaine, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 74 Plaza Dr, Pell City, AL 35125 Phone: 205-814-9284 Fax: 205-814-9626 | |
Lisa Ellison, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 70 Plaza Dr, Pell City, AL 35125 Phone: 205-814-9284 Fax: 205-338-0865 |